Sana biotechnology reports third quarter 2023 financial results and business updates

Enrolling phase 1 ardent trial investigating sc291 in patients with refractory b-cell malignancies with initial data expected in 2023 and more robust data in 2024

SANA Ratings Summary

SANA Quant Ranking